DE602005008639D1 - Behandlung von entzündungen - Google Patents

Behandlung von entzündungen

Info

Publication number
DE602005008639D1
DE602005008639D1 DE602005008639T DE602005008639T DE602005008639D1 DE 602005008639 D1 DE602005008639 D1 DE 602005008639D1 DE 602005008639 T DE602005008639 T DE 602005008639T DE 602005008639 T DE602005008639 T DE 602005008639T DE 602005008639 D1 DE602005008639 D1 DE 602005008639D1
Authority
DE
Germany
Prior art keywords
a3ar
inflammatory state
subject
level
wbc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602005008639T
Other languages
English (en)
Inventor
Pnina Fishman
Sara Bar-Yehuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Can Fite Biopharma Ltd
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005008639(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of DE602005008639D1 publication Critical patent/DE602005008639D1/de
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
DE602005008639T 2004-12-02 2005-11-30 Behandlung von entzündungen Expired - Fee Related DE602005008639D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63219804P 2004-12-02 2004-12-02
US65771805P 2005-03-03 2005-03-03
PCT/IL2005/001280 WO2006059328A1 (en) 2004-12-02 2005-11-30 Treatment of inflammation

Publications (1)

Publication Number Publication Date
DE602005008639D1 true DE602005008639D1 (de) 2008-09-11

Family

ID=35708899

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602005015135T Active DE602005015135D1 (de) 2004-12-02 2005-11-30 Biologischer marker für entzündung
DE602005008639T Expired - Fee Related DE602005008639D1 (de) 2004-12-02 2005-11-30 Behandlung von entzündungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE602005015135T Active DE602005015135D1 (de) 2004-12-02 2005-11-30 Biologischer marker für entzündung

Country Status (13)

Country Link
US (3) US20080056992A1 (de)
EP (2) EP1817079B1 (de)
JP (2) JP4842964B2 (de)
KR (2) KR20070090222A (de)
AT (2) ATE402739T1 (de)
AU (2) AU2005310874B2 (de)
BR (2) BRPI0518795A2 (de)
CA (2) CA2586774A1 (de)
DE (2) DE602005015135D1 (de)
DK (1) DK1817079T3 (de)
ES (2) ES2327435T3 (de)
MX (2) MX2007006501A (de)
WO (2) WO2006059328A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043054A1 (en) * 2005-10-12 2007-04-19 Can-Fite Biopharma Ltd. Treatment and monitoring disease state of liver cancer
ATE540673T1 (de) * 2005-11-30 2012-01-15 Can Fite Biopharma Ltd Verwendung von a3-adenosin-rezeptor-agonisten bei der behandlung von osteoarthritis
US20080183101A1 (en) * 2006-08-17 2008-07-31 Jonathan Richard Stonehouse Salivary analysis
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2008056361A1 (en) * 2006-11-09 2008-05-15 Can-Fite Biopharma Ltd. A biological marker for psoriasis
HUE034474T2 (en) 2007-03-14 2018-02-28 Can Fite Biopharma Ltd Method for the synthesis of IB-meca
IL200753A (en) * 2009-09-06 2015-06-30 Can Fite Biopharma Ltd Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
MX2012010006A (es) * 2010-03-03 2013-01-17 Us Gov Health & Human Serv Agonistas de a3ar para el tratamiento de uveitis.
WO2011158904A1 (ja) * 2010-06-18 2011-12-22 株式会社林原生物化学研究所 アデノシンｎ１－オキシドを有効成分として含有する炎症性疾患治療剤
KR102095284B1 (ko) 2017-05-11 2020-04-01 (주)케어젠 메토트렉세이트와 펩타이드의 결합체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61502124A (ja) 1984-05-09 1986-09-25 ジ　オ−ストラリアン　ナシヨナル　ユニヴア−シテイ− 免疫応答の調節方法
AU5182500A (en) 1996-08-01 2000-10-26 Kennedy Institute Of Rheumatology, The Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
DE69724451T2 (de) 1996-12-06 2004-03-18 Amgen Inc., Thousand Oaks Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
US20020179549A1 (en) * 2001-06-04 2002-12-05 Chris Felcman System and method for mounting a keyboard and display assembly in a 1U rack space
JP2004135657A (ja) * 2002-08-21 2004-05-13 Kyowa Hakko Kogyo Co Ltd ヒトａ３アデノシン受容体を発現するトランスジェニック非ヒト哺乳動物
EP1554574A2 (de) * 2002-10-21 2005-07-20 Can-Fite Biopharma Ltd. Diagnostische marker für therapeutische behandlung
US20040229246A1 (en) * 2002-10-21 2004-11-18 Can-Fite Biopharam Ltd. Diagnostic markers for therapeutic treatment
AU2003274648A1 (en) * 2002-10-22 2004-05-13 Can-Fite Biopharma Ltd. The use of the a3 adenosine receptor as a marker for a diseased state
AU2003282359A1 (en) * 2002-11-19 2004-06-15 Can-Fite Biopharma Ltd. A3ar agonists for the treatment of inflammatory arthritis
WO2004086034A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
JP2007526230A (ja) 2003-06-25 2007-09-13 エラン ファーマシューティカルズ，インコーポレイテッド 関節リウマチを治療する方法および組成物
JP2007517019A (ja) 2003-12-29 2007-06-28 カン−フィテ・バイオファーマ・リミテッド 多発性硬化症の治療方法

Also Published As

Publication number Publication date
US8541182B2 (en) 2013-09-24
CA2586773C (en) 2018-03-27
EP1817589B1 (de) 2009-06-24
WO2006059328A1 (en) 2006-06-08
ES2309817T3 (es) 2008-12-16
JP4842964B2 (ja) 2011-12-21
ATE434762T1 (de) 2009-07-15
AU2005310874A1 (en) 2006-06-08
EP1817589A1 (de) 2007-08-15
AU2005310873A1 (en) 2006-06-08
ES2327435T3 (es) 2009-10-29
WO2006059327A1 (en) 2006-06-08
KR20070090222A (ko) 2007-09-05
DE602005015135D1 (de) 2009-08-06
DK1817079T3 (da) 2008-11-17
MX2007006501A (es) 2007-07-13
CA2586774A1 (en) 2006-06-08
EP1817079B1 (de) 2008-07-30
AU2005310874B2 (en) 2008-11-27
KR20070100261A (ko) 2007-10-10
ATE402739T1 (de) 2008-08-15
EP1817079A1 (de) 2007-08-15
CA2586773A1 (en) 2006-06-08
AU2005310873B2 (en) 2008-11-27
JP2008522182A (ja) 2008-06-26
US20080056992A1 (en) 2008-03-06
BRPI0518777A2 (pt) 2008-12-09
US20130345163A1 (en) 2013-12-26
MX2007006500A (es) 2007-07-13
BRPI0518795A2 (pt) 2008-12-09
US20100256084A1 (en) 2010-10-07
JP2008521883A (ja) 2008-06-26

Similar Documents

Publication Publication Date Title
ATE402739T1 (de) Behandlung von entzündungen
Yang et al. Glutaminolysis: a hallmark of cancer metabolism
Burston et al. Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
EA202091230A3 (ru) Антагонисты активин-actrii и их применения для повышения уровней эритроцитов
Błogowski et al. Clinical analysis of perioperative complement activity during ischemia/reperfusion injury following renal transplantation
WO2007123976A3 (en) Antibody profiling for determination of patient responsiveness
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
WO2005103281A3 (en) Platelet biomarkers for the detection of disease
EA201400197A1 (ru) Имидазопиразиновые ингибиторы тирозинкиназы syk
ATE435015T1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
WO2009025847A3 (en) Methods for diagnosis, prognosis and methods of treatment
ATE548050T1 (de) Diagnoseverfahren
DK1421215T3 (da) Fremgangsmåder til evaluering af patologiske tilstande under anvendelse af ekstracellulært RNA
NZ610356A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ATE556717T1 (de) Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
DE602005023725D1 (de) Diagnose und überwachung von entzündlichen krankheiten mittels messung der zusätzlichen komponenten von leukozyten
EA200500218A1 (ru) ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β
EP1718768A4 (de) Verfahren und zusammensetzungen zur bestimmung eines transplantationstoleranten phänotyps in einem individuum
EA201201113A1 (ru) Способы и соединения для роста мышц
WO2007044622A8 (en) Use of mif and mif pathway agonists
MX2017013390A (es) Método para el tratamiento de cáncer pulmonar.
CY1111356T1 (el) Βελτιστοποιηση της θεραπειας της θετικης στο χρωμοσωμα της φιλαδελφειας λευχαιμιας με ιματινιμπη, εναν αναστολεα κινασης τυροσινης toy abl

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee